Enhertu Reimbursement Analysis: Navigating Cost...

By João L. Carapinha

June 5, 2025

The Dutch Healthcare Institute (ZIN) has recommended trastuzumab deruxtecan (Enhertu) for inclusion in the Netherlands’ basic insurance package for HER2-low metastatic breast cancer. This recommendation is contingent on a pric...